Equities

Lyra Therapeutics Inc

LYRA:NMQ

Lyra Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1796
  • Today's Change0.002 / 0.90%
  • Shares traded2.95m
  • 1 Year change-94.24%
  • Beta-0.1025
Data delayed at least 15 minutes, as of Nov 21 2024 20:53 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform1
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Lyra Therapeutics Inc have a median target of 1.25, with a high estimate of 2.00 and a low estimate of 0.50. The median estimate represents a 602.25% increase from the last price of 0.178.
High1,023.6%2.00
Med602.2%1.25
Low180.9%0.50

Earnings history & estimates in USD

On Nov 12, 2024, Lyra Therapeutics Inc reported 3rd quarter 2024 losses of -0.18 per share. This result exceeded the -0.23 consensus loss of the 5 analysts covering the company and exceeded last year's 3rd quarter results by 33.33%.
The next earnings announcement is expected on Mar 19, 2025.
Average growth rate-19.08%
Lyra Therapeutics Inc reported annual 2023 losses of -1.26 per share on Mar 21, 2024.
Average growth rate+15.73%
More ▼

Revenue history & estimates in USD

Lyra Therapeutics, Inc. had 3rd quarter 2024 revenues of 195.00k. This missed the 320.00k consensus estimate of the 5 analysts following the company. This was 52.44% below the prior year's 3rd quarter results.
Average growth rate+34.06%
Lyra Therapeutics, Inc. had revenues for the full year 2023 of 1.56m. This was 14.31% above the prior year's results.
Average growth rate+196.28%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.